Mutual of America Capital Management LLC raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 3.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,838 shares of the biopharmaceutical company’s stock after buying an additional 8,044 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $16,753,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tradewinds Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth $111,000. American National Bank grew its holdings in shares of Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares in the last quarter. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Finally, BDO Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth $123,000. 69.82% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market capitalization of $102,154.63, a PE ratio of 21.09, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 earnings per share. equities research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.

Several research firms have recently issued reports on BMY. Jefferies Group reissued a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Cowen restated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Credit Suisse Group restated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 8th. Finally, Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $64.93.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/18/mutual-of-america-capital-management-llc-raises-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.